A 58-year-old man with moderate COPD is started on maintenance bronchodilator therapy. Among the mechanisms of action of common bronchodilators, which is the most frequently targeted mechanism in clinical practice?

Explanation

## Most Common Bronchodilator Mechanism: Beta-2 Agonism **Key Point:** Beta-2 adrenergic receptor agonism, which increases intracellular cAMP and causes smooth muscle relaxation, is the most commonly exploited mechanism in COPD maintenance therapy worldwide. ### Mechanism of Beta-2 Agonists **High-Yield:** Beta-2 agonists bind to β~2~-adrenergic receptors on airway smooth muscle, activating adenylyl cyclase and increasing cAMP levels: $$\text{β}_2\text{-AR activation} \rightarrow \text{↑ Adenylyl cyclase} \rightarrow \text{↑ cAMP} \rightarrow \text{Smooth muscle relaxation}$$ ### Why Beta-2 Agonism Dominates **Clinical Pearl:** - LABAs (salmeterol, formoterol) are the single most prescribed class globally - Rapid onset of action (5–15 minutes) - Potent bronchodilation with proven exacerbation reduction - Excellent safety profile with decades of clinical experience - Available in multiple formulations (MDI, DPI, nebulizer) ### Comparative Mechanisms in COPD Therapy | Mechanism | Drug Class | Onset | Duration | Frequency in Practice | |---|---|---|---|---| | **β~2~ agonism (↑cAMP)** | SABA, LABA | 5–15 min | 4–24 hrs | **Most common** | | M3 antagonism (ACh block) | SAMA, LAMA | 30–60 min | 6–24 hrs | Common (alternative) | | PDE inhibition (↑cAMP) | Methylxanthines | 30–60 min | 6–8 hrs | Rare (obsolete) | | Leukotriene antagonism | Montelukast | 2–4 hrs | 12–24 hrs | Not for COPD maintenance | **Mnemonic:** **β~2~-CAMP** — Beta-2 agonists increase cAMP, causing Airway Muscle relaxation and Persistent bronchodilation. ### Why Other Mechanisms Are Less Common 1. **Muscarinic antagonism (M3 blockade):** Second-line alternative, slower onset, less potent than β~2~ agonists, but increasingly used in combination therapy. 2. **Phosphodiesterase inhibition:** Theophylline is rarely used due to narrow therapeutic index and drug interactions; modern practice has abandoned this approach. 3. **Leukotriene antagonism:** Primarily used in asthma, not indicated for COPD maintenance; no role in obstructive airway disease management. ### Dual-Mechanism Advantage Modern COPD therapy often combines β~2~ agonism with M3 antagonism (LABA/LAMA) to target both pathways synergistically, but β~2~ agonism remains the cornerstone. [cite:KD Tripathi 8e Ch 16; Harrison 21e Ch 258]